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Polyvalent mechanical bacterial lysate (PMBL) has been reported to be effective in the prevention of 
common respiratory tract infections. PMBL are produced through a process that preserves the 
structure of the bacterial antigens and because of their immunogenic capabilities, increasing 
importance is given to its mechanism of action, not yet fully understood. Respiratory tract epithelial 
cells constitute a front-line physical barrier between the organism and the environment. They are able 
to sense pathogen associated molecular patterns and secrete a wide spectrum of protective factors. By 
using primary normal Human Bronchial Epithelial Cells (HBEpiCs), we observed that PMBL can 
improve epithelial barrier integrity via induction of adhesion molecules. Along with adhesion 
molecules, PMBL had a significant effect on epithelial cell proliferation increasing the expression of 
the autocrine growth factor Amphiregulin (AR). Moreover, treatment with PMBL promoted ex-novo 
gene expression of human beta-defensin 2 (HβD-2) on HBEpiCs and conferred them a direct 
antimicrobial activity. Epithelial cells are structural components of mucosal immunity that include 
also dendritic cells (DCs) and innate lymphoid cell-type 3 (ILC3s). PMBL induced IL-23 and IL-1β 
secretion by DCs that, in turn, activate ILC3s to produce IL-22, cytokine primarily involved in the 
induction of antimicrobial peptides (AMPs). Interestingly, IL-23 produced by DCs can also activate 
epithelial cells and lead to a boost of IL-22 production by ILC3s. Remarkably, HβD-2 and LL-37 
AMPs can be induced in the saliva of normal subjects after administration of PMBL. Altogether, 
these results indicate that PMBL administration might support a critical barrier-protective immune 
pathway that originates from, and is orchestrated by airway epithelial cells and could be 





Polyvalent Mechanical Bacterial Lysate 
 
Respiratory tract infections represent one of the most common causes of human disease in terms of 
morbidity, mortality, and economic cost worldwide. Usually, respiratory system is considered as a 
sterile environment, by which pass air breathing. On the contrary, airway system is constantly 
exposed to airborne pathogens and environmental particles. Respiratory diseases are one of the main 
causes of human death around the world: <<About 65 million people suffer from chronic obstructive 
pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of 
death worldwide. About 334 million people suffer from asthma, the most common chronic disease of 
childhood affecting 14% of all children globally. Pneumonia kills millions of people annually and is 
a leading cause of death among children under 5 years old. Globally, 4 million people die 
prematurely from chronic respiratory disease>> (1). At the moment, a large spectrum of different 
therapeutic options is available, essentially based on administration of antibiotics. Beside these, 
bacterial lysates have obtained a progressively larger consensus in the medical practices, since they 
seem preventing upper and lower respiratory tract infections in both pediatric and elder ages (2). 
Bacterial lysates are mixtures of bacterial antigens derived from different microbial species. Antigens 
are obtained using a chemical (PCBL) or mechanical (PMBL) cellular lysis. PMBL are produced 
through a process that preserves the structure of bacterial antigens and because of their immunogenic 
capabilities, they are commonly used as immunomodulators able to induce a range of effects on the 
immune system (3,4). These effects include enhanced expression of adhesion molecules on 
monocytes and neutrophils, activation of dendritic cells, T and B lymphocytes, IgA secretion, as well 
as the production of antibodies directed against administered bacterial antigens. For example, 
IsmigenÔ, a PMBL of 13 different bacterial strains, has been reported  to induce the activation of 
DCs, leading to a significantly higher expression of co-stimulating membrane molecules (CD80, 
CD83, CD86). Furthermore, another study revealed that this PMBL activated IL-2 receptor (IL-2R) 
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on both B and T lymphocytes  and promote cytokine synthesis (IL-2, IL-10, IL-12, IFN-g) in immune 
competent cells, thus significantly regulating immune responses. Although these important 
evidences, the immunologic mechanism of action of bacterial lysates is not yet clearly determined.  
 
Epithelial cell barrier function 
 
In this regard, an interesting result was obtained in a murine model treated with an aerosolized lysate 
of ultraviolet-killed nontypeable (unencapsulated) Haemophilus influenzae (NTHi), then challenged 
with a lethal dose of live Streptococcus pneumonia (5). Upon exposition of mice to NTHi lysate, 
complete protection against Pneumococcal infection is recorded when the treatment is performed 
between 4 and 24 hours before bacterial infection (Figure 1A). The observed effect is due to innate 
immune mechanisms, because it occurs too rapidly for an adaptive immune response. In particular, it 
was associated with an induction of protective response that did not depend on neutrophils, mast cells 
and alveolar macrophages, suggesting the presence of another cellular effector of this response 
(Figure 1B).  
 
(Clement CG et al., Am J Respir Crit Care Med, DOI: 10.1164/rccm.200607-1038OC) 
 
Figure 1. Supporting evidences of Mucosal Innate Immunity induced by bacterial lysate 
Indeed, the very first step in the immune-activation resulting from PMBL is the interaction of the 
microbial particles with epithelial cells. The mucosal surfaces of the respiratory tracts are covered by 
a layer of epithelial cells that are responsible for sensing and promoting an host immune response 
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(6,7). The respiratory system is composed by upper (nasal passages, pharynx, larynx) and lower 
(trachea, bronchial tree, lungs) tracts with a whole mucosal surface area over than 70 m2 (8,9). 
Epithelium represents the protective coverage of inner and external mucosa and the first contact site 
of environmental particles and microbes (Figure 2). Mechanically, airway epithelium is composed 
by a continuous layer of basal, goblet, ciliated cells and mucus, determining a consistent physical 
barrier. In particular, the epithelial structural configuration is maintained by a large number of cell 
adhesion molecules (CAMs), involved in cellular junctions. The coexistence of dynamic physical 
structures together with active mechanisms of immune defense makes epithelium the first line defense 
of innate immune system. First, to preserve mucosal homeostasis and integrity, epithelial cells have 
the ability to reinforce barrier integrity improving the tightness of cellular junctions or regulating 
their proliferation. In particular, specialized cellular compartments require cell-to-cell adhesions or 
“synapses”, based on interaction between CAMs, to preserve their structure and function (10). For 
example, human mucosa need a way through which immune cells can transmigrate the blood or tissue 
and exit toward sites of inflammation. This way is represented by the dynamic adhesion between 
leukocytes and epithelial/endothelial cells (immunologic synapse). As well, the structural and 
functional distribution of cells in mucosal epithelium is due to cell-to-cell contact (epithelial synapse).  
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(LeMessurier KS et al., Front. Immunol. doi: 10.3389/fimmu.2020.00003) 
 
Figure 2. Structure of airway epithelium 
 
One of the main adhesion molecules involved in immunologic synapse is the intercellular adhesion 
molecule-1 (ICAM-1/CD54). It is a surface glycoprotein, constitutively expressed at low levels on 
hemopoietic and endothelial cells, fibroblasts and different epithelia (e.g., bronchial, kidney, urinary 
tract, and skin). Its expression is upregulated during inflammation by proinflammatory cytokines (e.g. 
TNF-a, IL-1, and IFN-g) and bacterial components such as LPS (11,12). Relevant studies showed 
that  ICAM-1 expression on epithelial cells promotes neutrophils and lymphocytes transmigration to 
the site of inflammation (13-15), facilitating the beginning of local immune response. 
 
In the context of epithelial synapse, Adherens Junctions (AJs), one of the main apical adhesive 
structures, maintain cellular tightness by homophilic interactions of E-Cadherin molecules (16). E-
cadherin is one of the classical cadherins, together with the neural cadherin (N-Cadherin), placental 
cadherin (P-Cadherin), and the vascular endothelial cadherin (VE-Cadherin). E-Cadherin is a 
transmembrane glycoprotein involved in Ca2+-dependent cellular junctions. The highly conserved 
intracellular domain of E-Cadherin is conjugated with a complex of α-, β- and p120-catenins (17). 
 6 
The interaction of E-Cadherin with this intracellular complex modulate its association with the 
cytoskeleton, its transport and recycling, and morphological polarity of epithelial cells (18). Thus, the 
primary function of E-Cadherin is to stabilize intercellular adhesion between adjacent cells, 
preserving the integrity of epithelium. Moreover, the stability of AJs prevents alteration and 
disruption of epithelial layer, maintaining tissue homeostasis and improving survival of the organism 
(19). 
 
Another important mechanism to maintain epithelial barrier integrity is due to the regulation of 
proliferation. In normal conditions, the muco-ciliary clearance preserves epithelial integrity, actively 
contrasting the microbial colonization. When the mucus layer is disrupted, epithelial injuries, derived 
by a direct interactions between epithelial cells and microbes or microbial compounds, determines 
the activation of host defense mechanism (Figure 3). In particular, baso-lateral TLRs of epithelial 
cells interact with microbial compounds, determining the secretion of autocrine proliferative factors, 
such as Amphiregulin (AR), an Epidermal Growth Factor Receptor ligand, promoting epithelial cell 
turn over and proliferation. (20,21) 
 
(Abreu, M. T., Nature Reviews Immunology, doi:10.1038/nri2707) 





Beside the physical mechanisms of host immune defense, epithelial cells have also the capability to 
directly kill microbial agents through the production of antimicrobial peptides (AMPs) (Figure 4).  
•  
(Christopher D. Fjell et al., Nature Reviews Drug Discovery, doi:10.1038/nrd3591)  
Figure 4. AMPs mechanism of action. 
 
Small cationic AMPs are synthetized and stored as pre-pro-peptides by epithelial cells and 
neutrophils. To become functional, AMPs are cleaved before secretion to obtain a cationic charge 
able to induce electrostatic interactions with anionic fragments of microbial membrane, determining 
the formation of ion pores and membrane disruption. The major lung epithelial AMPs are defensins 
and cathelicidins. Defensins are cationic peptides with a molecular mass of 3.5–4.5 kDa, that contain 
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six cysteine residues to form three characteristic intramolecular disulfide bridges. The disulfide 
bridge arrangement determines three different classes of defensins: α-defensins, β-defensins, and θ-
defensins. β-defensins are the only class of defensins produced by epithelial cells. β-defensins are 
cationic peptides with a broad-spectrum antimicrobial activity. They are composed by 36–42 amino-
acids and can be constitutive (e.g. HBD-1) or inducible (e.g. HBD-2) in different mucosal sites (skin, 
saliva, lung, intestine, kidney, urogenital tract) (22-24). 
About cathelicidins, they have an N-terminal domain (cathelin), involved in protein binding, and a 
C-terminal domain with antimicrobial activity. In human, we can find only a propeptide (CAMP or 
hCAP-18) which is cleaved to the active antimicrobial peptide, LL-37. This AMP shows an 
amphipathic α-helical structure able to bind lipopolysaccharides or teichoic acids of bacterial 
membrane. It is supposed that interaction between the hydrophobic components of helix and the lipid 
bilayer promotes distortion and disruption of the membrane, causing microbial death. (25).   
 
Mucosal Innate Immune Response 
 
All these evidences of an active antimicrobial role of epithelial cells demonstrate that epithelium is 
not a wooden barrier: it has plasticity and actively participates to innate immune response, by sensing 
the presence of bacterial components. Moreover, innate immune signaling derived from intact 
bacteria or microbial fragments in contact with epithelial cells, beyond mucus layer, produces a 
cascade reaction, by which resident leukocytes are enrolled for immune reaction to clear pathogens, 
promoting tissue repair (26). As intestinal mucosa, airway system is constantly exposed to 
environmental factors and microbial agents, derived from air breathing. In this scenario, tissue-
resident DCs play a pivotal role in recognition of pathogen-associated molecular patterns (PAMPs) 
to modulate mucosal immune response (27). In particular, DCs are able to sample beyond the lumen 
of mucosa that, in normal conditions, is covered by a thick layer of mucus, full of antimicrobial 
proteins and secretory IgA. In case of inflammation and mucosal injury, derived from bacterial 
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colonization, DC sampling results in their maturation and activation. Thus, activated DCs are able to 
orchestrate the local innate immune response, producing a large number of cytokines and chemokines 
to recruit innate immune cells (28). In particular, mucosal DCs show to be a relevant source of IL-23 
and IL-1b, the main soluble factors involved in activation of innate lymphoid cells-type 3 (ILC3s) 
(29-31) (Figure 5).  
 
(SJ Rubino et al., Trends in Immunology, doi:10.1016/j.it.2012.01.003) 
Figure 5. DCs and ILC3s cross-talk 
 
Innate lymphoid cells (ILCs) are a newly described heterogeneous population, representing the innate 
counterpart of CD4+ T-Helper cells (32). Indeed, ILCs lack of rearranged antigen receptors and have 
no demonstrated cytotoxic capacity, showing to be able to produce cytokines. Conventionally, ILCs 
are distinguished into three classes by their expression of transcription factors and cytokines and 
ILC3s are the main players of mucosal immune system. ILC3s express the transcription factor RORγt 
and represent a great innate source of IL-22 (33). In contrast to many other soluble factors, IL-22 
exerts its effect on nonhematopoietic epithelial cells and fibroblasts in tissues, such as lung. IL-22 is 
involved in induction of epithelial-derived antibacterial proteins, such as β-defensin 2, in proliferation 
of epithelial cells and epithelial repair after injury. In mucosal immunity, upon microbial infections 
and epithelial injury, IL-23 represents a potent inducer of IL-22 production (34). 
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Aim of the study 
 
Epithelial cells represent the first mucosal barrier and they are able to directly sense and response to 
bacterial stimuli (Figure 6).  
 
Figure 6. Host defense mechanism of epithelial cells 
To this reason, PMBL, that include bacterial components derived by several strains, may activate 
epithelial cell-mediated innate immune response against pathogens. In particular, considering the 
capability of epithelium to contrast microbial infections, we investigated whether PMBL is able to 
modulate epithelial cell adhesion, proliferation and, more important, to enhance the production of 
antimicrobial agents. Also, we evaluated the capability of PMBL to induce the production of DC-
derived IL-23, licensing the production of IL-22 by ILC3s, the main soluble factor involved in 
maintenance of mucosal integrity and production of AMPs. Therefore, we evaluated the capability of 
PMBL to reinforce in-vivo mucosal barrier, quantifying the expression of AMPs on saliva samples 





PMBL stimulates epithelial cell adhesion and proliferation. 
 
Microbial invasion can be facilitated by an alteration of epithelial barrier integrity, mainly regulated 
by junction proteins. To analyze whether PMBL can improve airway epithelial barrier functions, we 
threated a primary cell line of normal Human Bronchial Epithelial Cells (HBEpiCs) for 24 hours with 
PMBL and then assessed the expression of the adhesion molecules CD54 (ICAM-1) and CD324 (E-
Cadherin).  
 
ICAM-1 is constitutively expressed at low level on epithelial cells, but it can be upregulated in the 
early phase of bacterial infections (11). PMBL treatment increased ICAM-1 expression on HBEpiCs 
and a clear image of this upregulation was obtained by Image Stream cytometry analysis (Figure 
7A).  
 
Concerning E-cadherin, flow cytometry analysis revealed a mild upregulation of E-cadherin on 
HBEpiCs upon stimulation with PMBL, but immunofluorescence assay revealed a different 
distribution of this adhesion molecule. In particular, epithelial cells left untreated showed an 
intracellular and surface distribution of E-cadherin, whereas PMBL treatment induced a clear 
polarization to cell membrane (Figure 7B). In this regard, E-cadherin should be expressed on plasma 
membrane to be functional for cellular adhesion, while it can be partially internalized for recycling 
or degradation (18).  
 
The homeostasis of airway barrier is also based on the regulation of epithelial proliferation (21). To 
address whether PMBL can promote epithelial proliferation, we evaluated epithelial expression of 
Ki67 marker upon PMBL stimulation and we observed a higher frequency of Ki67+ HBEpiCs (Figure 
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7C), compared to unstimulated condition. Mechanistically, epithelial cell proliferation can be induced 
by the production of autocrine factors, such as Amphiregulin (AR) and HBEpiCs stimulated with 
PMBL for 6h showed an induction of AR gene expression (Figure 7D). Altogether, these results 




Figure 7. PMBL increased the expression of adhesion molecules and proliferative factors on HBEpiCs. (A) Surface expression 
of ICAM-1 was assessed on HBEpiCs stimulated or not for 24 hours with PMBL by flow cytometry and Image Stream cytometry. 
(Left) Bars represent mean fluorescence intensity (MFI) values ± SEM of ICAM-1 from three independent experiments. (Right) 
Comparative Brightfield (BF), DRAQ5 (nucleus), ICAM-1 and MERGE profile of HBEpiCs are shown. Scale bar = 7 µm. (B) Analysis 
of E-cadherin expression on HBEpiCs stimulated or not for 24 hours with PMBL by flow cytometry and immunofluorescence assay. 
(Left) Bars represent MFI values ± SEM of E-Cadherin from three different experiments. (Right) Fluorescence Microscopy analysis of 
E-Cadherin expression. Representative images of three independent experiments are shown. Scale bar = 20 µm. (C) Proliferation was 
assessed on HBEpiCs stimulated or not for 24 hours with PMBL by intranuclear Ki67 staining. Representative dot plots of three 
independent experiments show the percentage of Ki67+ cells. Bars represent mean values ± SEM of Ki67+ HBEpiCs. (D) AR gene 
expression was measured by RT-PCR on HBEpiCs stimulated or not with PMBL for 6 hours. Data derived from three different 
experiments. Bars represent Fold Change values ± SEM of AR mRNA expression of HBEpiCs.  *P < .05, **P < .01; Student t-test.  
 
PMBL enhances epithelial antimicrobial activity via release of AMPs. 
 
Administration of PMBL has been reported to prevent recurrent respiratory tract infections (rRTI) 
(35). Epithelial cells can sense PAMPs and, along with forming a physical barrier against infection, 
can exert a direct antimicrobial activity by producing antimicrobial peptides (AMPs). Human beta 
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defensin-2 (HBD-2) is a major antimicrobial peptide produced by many types of epithelial cells and 
it is transcriptionally inducible by various proinflammatory agents, such as cytokines and bacteria. 
 
We, therefore, investigated whether epithelial cells can respond to PMBL treatment by augmentating 
antimicrobial defenses and both RT-PCR and gel electrophoresis analyses revealed ex-novo growing 
induction of HBD-2 gene expression on HBEpiCs, between 6h and 24h of stimulation with PMBL 
(Figure 8A). Then, we assessed the direct antimicrobial activity of epithelial cells treated with PMBL 
by performing an antimicrobial sensitivity testing, after conditioning with epithelial cell derived 
supernatants. In agreement with ex-novo expression of HBD-2, supernatants of PMBL-stimulated 
epithelial cells significantly reduced S. Aureus colony-forming units (CFU) (Figure 8B). Thus, 
PMBL is able to induce the production of epithelial AMPs that might support mucosal “Stimulated 
Innate Resistance (StIR)” to microbial infections (24). 
 
 
Figure 8. PMBL induced ex-novo gene expression of HBD-2 on HBEpiCs and promoted their direct antimicrobial activity on 
live S.Aureus.  (A) HBD-2 gene expression was measured by RT-PCR and gel-electrophoresis on HBEpiCs stimulated or not with 
PMBL for 6 and 24 hours. Data derived from three different experiments. Bars represent Fold Change values ± SEM of HBD-2 mRNA 
expression of HBEpiCs (B) Antimicrobial sensitivity testing was performed by conditioning with HBEpiC culture supernatants 100 
CFU/mL of live S. Aureus for 5 hours. The experiment was performed in triplicate. Bars represent the number of CFU ± SEM of S. 
Aureus bacteria. (**P < .01; Student t-test). 
 




Epithelial cells are structural components of mucosal immune network, physically related to other 
innate immune players, such as dendritic cells (DCs) and innate lymphoid cells-type 3 (ILC3s) (34, 
36). 
 
Production of IL-23 by DCs supports innate IL-22 secretion and binding of IL-22 to the IL-22 
receptor expressed on the epithelium can have multiple effects, including the enhanced secretion of 
antimicrobial peptides. The administration of PMBL induced the maturation of DCs (Figure 9A). 
Along with maturation markers, we observed that PMBL, but not other maturation stimuli, can induce 
on DCs the expression of CD103 and Langerin (Figure 9B), both typical markers of DCs 
preferentially localized within the epithelial layer. Moreover, PMBL-stimulated DCs produced high 
amounts of both IL-23 and IL-1b (Figure 9C) that supported in turn IL-22 production by ILC3s 
(Figure 9D, upper panel). Although the epithelium has been mainly thought to “passively” receive 
cytokine signals and transduce them into an antimicrobial response, we here observed that airway 
epithelial cells boosted IL-22 produced by ILC3s (Figure 9D, middle panel), becoming a crucial 
active player in orchestrating mucosal IL-22 production. It was recently reported that IL-23R 
signaling on intestinal epithelial cells can support protective mucosal IL-22 production. In line with 
this report, in the presence of IL-23 blocking antibody, airway epithelial cells lose the capability to 
support IL-22 production by ILC3s (Figure 9D, lower panel), thus clearly suggesting that epithelial 
cell licensing of mucosal IL-22 production is mediated by IL-23.  Altogether, these findings revealed 
that PMBL can also promote an indirect induction of AMPs by supporting mucosal IL-22 production. 
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Figure 9. PMBL activated epithelial cells via IL-23 produced by DCs, resulting in a boost of IL-22 secreted by ILC3s. (A) 
Expression of costimulatory/activation molecules CD40 and CD80 on unstimulated DCs and DCs stimulated 24 hours with PMBL was 
assessed by flow cytometry. A representative multiple overlay histogram of three different experiments is shown (B) CD103 and 
Langerin expression were assessed on DCs left untreated or stimulated with PMBL, LPS, or CYTOMIX (TNF-a+IFN-g) by flow 
cytometry. One representative experiment out of three is shown. (C) IL-23 and IL-1b concentration was assessed by ELISA assay in 
supernatants of DCs stimulated with PMBL for 48 hours and of unstimulated DCs, as control. Bars represent the mean values ± SEM 
of IL-23 (left) and IL-1b (right) concentration. (D) intracellular expression of IL-22 was assessed on ILC3s upon overnight stimulation 
in the indicated culture conditions. (Upper panel) ILC3s alone were stimulated with PMBL or supernatant of DCs cultured 48 hours 
with/without PMBL. Also, (middle panel) ILC3s were co-cultured with HBEpiCs at ratio 1:5 and stimulated in the same conditions. 
In specific experiments, (lower panel) DC supernatants were incubated with IL-23 blocking antibody, before stimulation of 
ILC3/HBEpiC co-culture. One representative experiment of three is shown in every panel. Data from all the experiments are 
summarized in the bars as percentage ± SEM of IL-22+ ILC3s. (**P < .01; Student t-test). 
 
Expression of AMPs on human saliva samples upon administration of PMBL. 
 
PMBL (IsmigenÔ) is a sublingually delivered formulation able to activate local mucosal immunity. 
Thus, we investigated whether PMBL administration could induce in normal subjects a local 
production of AMPs. To address this issue, we collected human saliva samples in 8 healthy volunteers 
under basal conditions, after sublingual administration of 1 tab of IsmigenÔ for consecutive 10 days 
and for the next 20 days (Table 1). By using ELISA technique, we quantified the amount of inducible 
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HBD-2 and LL-37, respectively belonged to the group of b-defensins and cathelicidins. Significant 
increased levels of these AMPs following bacterial challenge were obtained in 5/8 volunteers. In 
particular, after PMBL administration, AMP concentration increased, reaching significant higher 
level at day 6 for HBD-2 (Figure 10A) and at day 10 for LL-37 (Figure 10B). This effect seems to 
be specific since once PMBL administration is stopped, both HBD-2 and LL-37 levels went 
progressively down. Altogether, these results confirm that one of the relevant mechanisms of action 
of PMBL relies on the induction of antimicrobial peptides which can prevent colonization of host 
tissues by a range of pathogens at nanomolar concentration. 
 
 
Figure 10. Sublingual administration of PMBL improved salivary concentration of AMPs in healthy subjects. (A) HBD-2 and 
(B) LL-37 detection by ELISA assay in saliva samples of healthy subjects, at baseline (BS), during the administration of PMBL 
(IsmigenÔ) (Day3-Day10) and, during the next twenty days (Day13-Day30). Data of each protein derived from 5 of 8 healthy subjects. 




The spread of antibiotic resistance among bacteria responsible for common respiratory infections has 
prompted calls for an improvement or a reduction of antibiotic usage (37,38). The use of antibiotics 
was significantly reduced thanks to the treatment with PMBL™, representing a valid immunization 
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approach in fighting the spread of antibiotic resistance. Thanks to its administration route 
(sublingual), PMBL treatment can favor the activation of mucosal immune-surveillance, an important 
first line of defense. In the present study, we demonstrated that PMBL improves a critical barrier-
protective immune pathway by promoting a number of independent epithelial cell functions.  
Stimulation with PMBL can improve epithelial barrier integrity via both induction of adhesion 
molecules and proliferation. In addition, epithelium activated by PMBL shows a direct antimicrobial 
activity, since secreted HBD-2, an epithelium-specific antimicrobial protein. This change in epithelial 
cell functional capability is extremely relevant in defense against bacterial responsible for common 
respiratory infections and viral pneumonia. Indeed, AMPs are able to rapidly kill a broad range of 
infective agents and mechanisms that reduced antimicrobial protein expression resulted in microbial 
invasion and pathogenicity. Proof of this concept is provided by transgenic overexpression of HD-5 
expression in Paneth cells that, enhancing microbial killing and host defense, made mice resistant to 
an oral challenge with virulent Salmonella typhimurium (39). We also establish that lung epithelial 
cells require co-stimulation by DCs to reinforce their effector response. Although DCs could not be 
stimulated by the lysate to directly kill extracellular bacteria, they can instruct epithelial cells to 
express antimicrobial proteins, through local signaling via IL-22 dependent mechanisms (40). Our 
results demonstrated that DCs stimulated with PMBL expressed CD103 and Langerin and secreted 
high amounts of both IL-23 and IL-1b inducing, in turn, IL-22 production by ILC3s. In line with this 
observation, intestinal tissue-resident lamina propria dendritic cells (LPDCs) expressing CD103 
rapidly produced high amounts of IL-23 following bacterial flagellin administration and drove IL-
22-dependent RegIIIγ production (41). Interestingly, it has been reported that Broad-spectrum 
antibiotic administration along with killing commensal bacteria in the gut, decreases Toll-like 
receptor (TLR)-dependent mucosal expression of antimicrobial factors, such as the bactericidal C-
type lectin RegIIIγ, leading to a predisposition to VRE colonization (42,43). Therefore, strategies to 
enhance the expression of antimicrobial peptides may be effective against increasingly antibiotic-
resistant bacterial pathogens. In light of the PMBL’s mechanism of action described here, its 
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administration in the setting of antibiotic treatment could thus restore AMPs expression in airway 
mucosal barrier and restrict colonization of pathogens. Although the epithelium has been mainly 
thought to “passively” receive cytokine signals and transduce them into an antimicrobial response, 
we here observed that epithelium represents a crucial modulatory factor of mucosal immune response 
stimulated by PMBL. In particular, IL-23 dependent activation of airway epithelial cells leads to a 
boost of IL-22 production by ILC3s, thus actively orchestrating antimicrobial and regenerative 
processes in the mucosa. The relevance of this protective pathway has been recently highlighted in a 
mouse model of intestinal inflammation where deficiency of IL-23R expression in intestinal epithelial 
cells resulted in an impaired mucosal IL-22 induction, reduced antimicrobial peptide expression, and 
an expansion of flagellated bacteria that lead mice to succumb to DSS colitis (44). Finally, after 
having investigated the mechanisms by which PMBL promote antimicrobial expression, we 
translated our in vitro results into human subjects. We demonstrated that PMBL administration have 
the ability to induce HBD-2 and LL-37 production in the saliva of normal subjects. However, 
identification of other antimicrobial peptides as well as the protection they confer against subsequent 
pathogen challenges represent relevant issues that should be addressed in order to acquire a 
therapeutic value in patients. In summary, our studies reveal great functional plasticity of airway 
epithelial cells upon PMBL stimulation. We gained more insights into the nature of innate immune 
defenses triggered by this complex mixture of bacterial antigen, identifying a protective immune 
pathway orchestrated by airways epithelial cells. Therapeutic manipulation of this pathway may be 
possible especially in clinical settings where antimicrobial and regenerative processes mediated by 
IL-22 secretion represent important protective factors. 
 
Material and Methods 
 
Polyvalent Mechanical Bacterial Lysate 
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Polyvalent Mechanical Bacterial Lysate (PMBL) is provided by Lallemand Pharma. PMBL contains 
a blend of 13 inactivated bacterial strains of common pathogens involved in infections of the upper 
and lower respiratory system (S. aureus, S. viridans, S. pyogenes, K. pneumoniae, K. ozaenae, H. 
influenzae, N. catarrhalis and S. pneumoniae). For the experiments, the bacterial lysate was 
resuspended in PBS at 5 mg/ml, then added to the cell cultures at the final concentration of 100 µg/ml. 
 
Healthy volunteers and Study Design 
 
Saliva samples were obtained from 8 healthy volunteers aged between 26-53 years. All subjects were 
not affected by oropharyngeal inflammation and were not taking any medication at the beginning of 
the study. The study was approved by the institutional ethics committees of IRCCS Polyclinic 
Hospital San Martino, Genova (587/2020 - DB id 11025) and all participants gave written informed 
consent according to the Declaration of Helsinki. Volunteers assumed 1 tab of the commercial 
formulation of PMBL (IsmigenÔ) every 24 hours for 10 consecutive days. Saliva samples were 
obtained at baseline (BS), at six timepoints during IsmigenÔ administration (Day 3/Day 4/Day 5/Day 
6/Day 7/Day 10) and at further three timepoints along the next twenty days (Day 13/Day 17/Day 30). 




Peripheral blood was obtained from healthy donors and mononuclear cells (PBMCs) were separated 
over Ficoll density gradient centrifugation (30 minutes, 25°C, 2100 rpm). 
 
Tonsils tissues were obtained from patients undergoing tonsillectomy. 
 
Saliva samples were collected from healthy volunteers and processed as previously described (45). 
Briefly, we planned to collect saliva between 8–10 a.m. We asked subjects to refrain from eating, 
 20 
drinking or oral hygiene procedures for at least 1h prior to sampling. The subjects rinsed mouth out 
well with sterile-filtered distilled water and, 10 minutes later, approximately 5 mL of saliva were 
collected into pre-cooled 50 mL sterile tubes. Collection tubes were put into ice for up to 2 hours or 
immediately spinned for 30 seconds and then centrifuged at 3000 rpm for 10 minutes at 4°C, to pellet 
debris and mucoid components. Protease Inhibitor Cocktail (Sigma-Aldrich, Catalog Number: 
#P8340) was added to aliquots of 500 µL of saliva (dil. 1:500) and then samples were immediately 
stored at -80°C.  
 
All the samples were collected at the Immunology Unite of IRCCS Polyclinic Hospital San Martino, 
Genova.  
 
Cell isolation and culture 
 
For generation of DCs, monocytes were isolated from PMBCs by adherence to culture flasks for 45 
min at 37°C in 5% CO2. Subsequently, non-adherent cells were removed by washing with PBS. The 
resulting monocytes were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 
1 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 25 ng/ml human recombinant 
granulocyte–macrophage colony-stimulating factor (rGM-CSF) (Sargramostim) and 20 ng/ml human 
recombinant IL-4 (rIL-4) (Miltenyi Biotec). Resulting DCs were collected after 6 days.  
 
ILC3s were sorted and expanded as previously described. Briefly ILC3s were FACS-sorted from 
tonsil as LINneg (CD3, CD14, CD19, CD34, CD80 and BDCA2), CD127high CRTH2neg CD117+ 
NKp44+ cells and stimulated in 96-well round-bottom plates with irradiated PBMCs and irradiated 
721.221 tumor cells in the presence of PHA (1 ug/ml, Life Technologies), IL-2 (100U/ml, proleukin; 
Chiron) and IL-7 (10 ng/ml, Miltenyi). Cells were cultured in RPMI 1640 medium supplemented 
with 1% human AB serum. Cytokines were replaced every 2–3 days.  
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Primary Cell Lines 
 
Normal Human Bronchial Epithelial Cells (HBEpiC, Catalog Number: #3210) were purchased from 
ScienCell (ScienCell Research Laboratories, San Diego, California). HBEpiCs were cultured at 37°C 
in a 5% CO2 incubator using a serum-free Bronchial Epithelial Cell Medium complemented with 





In our experiments, HBEpiCs were grown to confluence in multiwell flat-bottom plate and stimulated 
with PMBL at the final concentration of 100 µg/ml. To evaluate the expression of ICAM-1 and E-
Cadherin, HBEpiCs were stimulated or not with PMBL for 24 hours and then analyzed by different 
immunofluorescence assays. 
 
To evaluate HBEpiC proliferation, cells were starved overnight in basal medium and then stimulated 
for 24 hours with PMBL in supplement medium. Then, cells were harvested and analyzed for the 
expression of Ki67 marker. In addition, cells were stimulated with PMBL for 6 hours and cell pellets 
were harvested to analyze the gene expression of AR.  
 
To assess the expression HBD-2, HBEpiCs were stimulated with PMBL for 6 and 24 hours, and then 
cell pellets were harvested to perform HBD-2 gene expression by both RT-PCR and gel-
electrophoresis analyses.  
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To evaluate the direct antimicrobial activity of epithelial cells, HBEpiCs were cultured in antibiotic-
free supplemented medium and stimulated with 100 ug/mL of PMBL or left untreated for 24 hours. 
Then, HBEpiC supernatants were collected to perform an antimicrobial sensitivity testing on live 
bacteria. 
 
To assess DC activation, moDCs were stimulated or not with PMBL for 48 hours and, then, both cells 
and culture supernatant were collected to evaluate expression of maturation markers and quantify 
cytokines, respectively. Alternatively, DC culture supernatants, collected in the same experimental 
conditions, were used to stimulate IL-22 production by ILC3s. In selected experiment, along with 
PMBL, DCs were stimulated with LPS (1 ug/ml) or CYTOMIX (IFN-g 1000 U/mL; TNF-a 100 
ng/mL).  
 
To evaluate IL-22 production on ILC3s, IL-22 expression was analyzed on ILC3s stimulated 
overnight with culture supernatants of DCs stimulated with PMBL or left untreated, in the presence 
of Golgi Stop and Golgi Plug (BD Bioscience). To evaluate the effect of HBEpiCs on IL-22 secretion, 
HBEpiCs were added to ILC3s (ratio 1:5) cultured in the above mentioned experimental conditions. 
In selected experiments, IL-23 blocking antibody (50 ug/mL) (Human IL-23 p19 Antibody, Catalog 




The following monoclonal antibodies (mAbs) were used in this study: anti-CD40 PE (clone 5C3, BD 
Biosciences), anti-CD45 (clone 2D1, BD Biosciences), anti-CD80 PE-Cy5 (clone L307.4,BD 
Biosciences), anti-CD80 FITC (clone L307.4, BD Biosciences), anti-CD103 BV421 (clone Ber-
ACT8, BioLegend), anti-Langerin PE (clone DCGM4, Beckman Coulter), anti-BDCA2 FITC (clone 
AC144, Miltenyi), anti-CD3 FITC (clone BW264/56, Miltenyi), anti-CD14 FITC (clone TÜK4, 
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Miltenyi), anti-CD34 FITC (clone AC136, Miltenyi), anti-CD19 VioBright FITC (clone LT19, 
Miltenyi), anti-CD117 BV421 (clone YB5.B8, BD Biosciences), anti-NKp44 PE (clone 2.29, 
Miltenyi), anti-CRTH2 PerCP-Cy5.5 (clone BM16, Biolegend), anti-CD127 PE/Dazzle 594 (clone 
A019D5, Biolegend), anti-ICAM-1 PE (clone HA58, BD Biosciences) and anti-E-Cadherin BV421 
(clone 67A4, BD Biosciences). For surface markers, cells were stained for 30 minutes at 4°C.  
 
For intracellular staining, upon surface staining, cells were fixed and permeabilized 
(Cytofix/Cytoperm Kit, BD Biosciences) according to the manufacturer’s protocol and incubated 
with anti-IL-22 e-fluor660 (clone 22URTI, Invitrogen) for 30 minutes at room temperature.  
 
For Intranuclear staining of Ki67 marker, fixation/permeabilization procedures, performed according 
to manufacturer’s protocol (eBioscence), were followed by incubation with anti-Ki67-BV421 mAb 
(clone B56) purchased from BD Bioscences.  
 
Dead cells were excluded by staining with LIVE/DEAD FIXABLE Aqua Dead dye (Invitrogen). 
Sample acquisition was performed on Gallios (Beckman Coulter) or MACSQuant (Miltenyi-Biotec) 
flow cytometers. Data were analysed by FlowJoVX (Tree Star Inc) software. 
 
Image Stream cytometry 
 
HBEpiCs were stained with anti-ICAM-1 and nuclear dye DRAQ5 and then analysed using Amnis 
Image Stream flow cytometer. After acquisition of focused single cells, we generated a compensation 
matrix, based on single-stained controls, performing our analysis with IDEAS 3.0 software. Briefly, 
we merged all acquisition files to apply a common gating strategy on DRAQ5+ cells, thus evaluating 
simultaneously ICAM-1 expression in every experimental conditions. Fluorescence intensity of each 
channel was normalized respect to unlabeled control. Finally, we showed images of single cells, 
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comparing the profile of Brightfield (Ch01), ICAM-1 (Ch03), DRAQ5 (Ch11) and channel merge 




Adherent HBEpiCs were washed twice prior of fixation in 2% paraformaldehyde (30 minutes, RT) 
and permeabilization in 0.1% Triton (10 minutes, RT). Staining with primary mAb mouse anti-human 
E-cadherin (clone 67A4, Santa Cruz biotech) was performed in PBS-BSA 1% (45 minutes, RT). 
Likewise, we stained with secondary mAb Alexa Fluor 594 goat anti-mouse IgG1 (30 minutes, RT). 
Finally, HBEpiCs were counterstained with DAPI using ProLong® Gold Antifade Mountant (Life 
Technologies). Day after, 20x images were captured using an ApoTome microscope with AxioCam 
(Karl Zeiss, Thornwood, NY, USA). 
 
RT-PCR and gel electrophoresis 
 
mRNA was extracted from pellets of HBEpiCs by using RNeasy MicroKit (QIAGEN, Catalog 
Number: #74004,). cDNA was synthesized by using Quantitect Reverse Transcription Reagents 
(QIAGEN, Catalog Number: #205311,). AR (Hs00950669_m1 - ThermoFisher Scientific) and HBD-
2 gene expression (Hs00175474_m1 - Thermofisher Scientific) was assayed by qPCR (Quant Studio 
DX real-time PCR system, ThermoFisher Scientific). mRNA content was normalized to b-actin 
expression. Mean relative gene expression was determined by using DDCT method. 
 
The product of HBD-2 gene amplifications was verified through size determination, resolving it on 
3% agarose gel stained with ethidium bromide. 
 
Microbial culture conditions 
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Staphylococcus aureus bacteria, used for the antimicrobial sensitivity testing, was a clinical strain 
obtained from our in-house culture collection kept at the University of Messina. Bacteria were grown 
in Mueller Hinton Broth (MHB; Oxoid, Milan, Italy) and Tryptic Soy Agar (TSA; Oxoid, Milan, 
Italy) at 37°C for 18-24 hours. 
 
Antimicrobial sensitivity testing 
 
Starting from a standard concentration of bacterial suspension (108 CFU/mL) determined with a 
spectrophotometer, we diluted bacteria in HBEpiC supernatants to a final concentration of 100 
CFU/mL. Then, samples were incubated in a thermostat shaker at 37°C. After 5 hours of conditioning, 
different dilutions of samples were plated in TSA plates, then incubated at 37°C for 18-24 hours. The 




Concentrations of cytokines (IL-23, IL-1b) and Amps (HBD-2, LL37) were measured on supernatants 
of DC cultures and saliva samples, respectively using validated commercially available ELISA kits. 
We used TMB ELISA kits for IL-23 (Catalog Number: #EH3270, FineTest), IL-1b (Catalog Number: 
#BGK01584, Biogens), and LL-37 (Catalog Number: #HK321-02, HycultBiotech) and ABTS ELISA 
kit for HBD-2 (Catalog Number: #900-K172, PEPROTECH).  
Briefly, we set for each assay a standard curve, obtained by 7 dilutions of standard protein plus blank 
condition. First step, 100 µL of properly diluted standards or samples (Targets) were added to coated 
wells in duplicate and incubated at room temperature. Next steps provided the sequential use of 
diluted Biotinylated Antibody (Detection Ab), Avidin/Streptavidin-HRP (peroxidase) conjugate, then 
a properly substrate (ABTS or TMB) to start 20-30 minutes of colorimetric reaction. Only for TMB 
ELISA, peroxidase reaction was stopped with Stop Solution after no more than 30 minutes. Finally, 
optical density (OD) for color development was monitored at a specific wavelength for each ELISA 
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kit using AD200 Plate Reader (Beckman Coulter). Protein concentration of our samples was derived 




A paired Student t test was used to evaluate statistical significance. P< .05 was considered statistically 
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